Ketamine Attenuates the Interleukin-6 Response After Cardiopulmonary Bypass
- 1 August 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 87 (2) , 266-271
- https://doi.org/10.1097/00000539-199808000-00006
Abstract
Cardiopulmonary bypass (CPB) has been proposed as a model for studying the inflammatory cascade associated with the systemic inflammatory response syndrome. Serum interleukin-6 (IL-6) concentration seems to be a good indicator of activation of the inflammatory cascade and predictor of subsequent organ dysfunction and death. Prolonged increases of circulating IL-6 are associated with morbidity and mortality after cardiac operations. In the present study, we compared the effects of adding ketamine 0.25 mg/kg to general anesthesia on serum IL-6 levels during and after elective coronary artery bypass grafting (CABG). Thirty-one patients undergoing elective CABG were randomized to one of two groups and prospectively studied in a double-blind manner. The patients received either ketamine 0.25 mg/kg or a similar volume of isotonic sodium chloride solution in addition to large-dose fentanyl anesthesia. Blood samples for analysis of serum IL-6 levels were drawn before the operation; after CPB; 4, 24, and 48 h after surgery; and daily for 6 days beginning the third day postoperatively. Ketamine suppressed the serum IL-6 response immediately after CPB and 4, 24, and 48 h postoperatively (P < 0.05). During the first 7 days after surgery, the serum IL-6 levels in the ketamine group were significantly lower than those in the control group (P < 0.05). On Day 8 after surgery, IL-6 levels were no different from baseline values in both groups. A single dose of ketamine 0.25 mg/kg administered before CPB suppresses the increase of serum IL-6 during and after CABG. In this randomized, double-blind, prospective study of patients during and after coronary artery bypass surgery, we examined whether small-dose ketamine added to general anesthesia before cardiopulmonary bypass suppresses the increase of the serum interleukin-6 (IL-6) concentration. Serum IL-6 levels correlate with the patient's clinical course during and after coronary artery bypass. Ketamine suppresses the increase of serum IL-6 during and after coronary artery bypass surgery.Keywords
This publication has 26 references indexed in Scilit:
- IL-6: Insights into Novel Biological ActivitiesClinical Immunology and Immunopathology, 1997
- IL-6 and APPs: anti-inflammatory and immunosuppressive mediatorsImmunology Today, 1997
- The Role of Proinflammatory Cytokines in Inflammatory and Metabolic ResponsesAnnals of Surgery, 1997
- The role of cytokines in cardiac surgeryInternational Journal of Cardiology, 1996
- Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failureThe Annals of Thoracic Surgery, 1993
- Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis SyndromeAnnals of Internal Medicine, 1993
- Inflammatory response to cardiopulmonary bypassThe Annals of Thoracic Surgery, 1993
- Circulating endotoxin and tumor necrosis factor during pediatric cardiac surgeryCritical Care Medicine, 1992
- Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivoClinical Immunology and Immunopathology, 1989
- Stimulation of Interleukin‐6 mRNA Levels by Tumor Necrosis Factor and Interleukin‐1Annals of the New York Academy of Sciences, 1989